Listed

INNOVATE Corp.: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on May 6, 2025 and accepted by EDGAR at May 6, 2025, 16:16 ET.

Share

Management's discussion and analysis

As filed, 84,421 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated annual audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025 (the "2024 Annual Report"), and the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section in our 2024 Annual Report as well as the section below entitled "Special Note Regarding Forward-Looking Statements" for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Unless the context otherwise requires, in this Quarterly Report on Form 10-Q, "INNOVATE" means INNOVATE Corp. and the "Company," "we" and "our" mean INNOVATE together with its consolidated subsidiaries. "U.S. GAAP" means accounting principles accepted in the United States of America.

Our Business and Our Operations

We are a diversified holding company with principal operations conducted through three operating platforms or reportable segments: Infrastructure ("DBMG"), Life Sciences ("Pansend"), and Spectrum, plus our Other segment, which includes businesses that do not meet the separately reportable segment thresholds.

For additional information on our business, refer to Note 1. Organization and Business included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Cyclical Patterns

Our segments' operations can be highly cyclical. Our volume of business in our Infrastructure segment may be adversely affected by declines or delays in projects, which may vary by geographic region. Project schedules, particularly in connection with large, complex, and longer-term projects can also create fluctuations in the services provided, which may adversely affect us in any given period.

For example, in connection with larger, more complicated projects, the timing of obtaining permits and other approvals may be delayed, and we may need to maintain a portion of our workforce and equipment in an underutilized capacity to ensure we are strategically positioned to deliver on such projects when they move forward.

Examples of other items that may cause our results or demand for our services to fluctuate materially from quarter to quarter include: weather or project site conditions; the spending patterns, including seasonal trends, and financial condition of our customers and their access to capital; our profit margins on projects performed during any particular period; rising interest rates and inflation; and regulatory, economic, political and market conditions on a regional, national or global scale.

Accordingly, our operating results in any particular period may not be indicative of the results that can be expected for any other period.

Recent Developments

We continually evaluate strategic and business alternatives within our operating segments, which may include the following: operating, growing or acquiring additional assets or businesses related to current or historical operations; or winding down or selling our existing operations. In the longer-term, we may evaluate opportunities to acquire assets or businesses unrelated to our current or historical operations. In the event we were to enter into a strategic transaction to sell any of our existing operations, our intention is to use available proceeds from such transaction to address our capital structure.

In 2025, as part of our strategic process, we engaged in several transactions that had or will have an effect on the results of operations and financial condition of our business and individual segments.

Debt Obligations and Financing

During 2025 thus far, we have refinanced some of our debt, including at the subsidiary level. This financing helped us provide needed capital for our operations and the operations of our subsidiaries.

Life Sciences

R2 Technologies has a short-term note with Lancer Capital. The stated interest on the note, as amended, is 20% and is payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest is capitalized monthly into the principal balance. During the first quarter of 2025, with an effective date of December 31, 2024, the maturity date of the note was extended to August 1, 2025, and another additional exit fee of $1.0 million was incurred under the amendment, which continues to increase by $1.0 million each month until maturity. The base exit fee, as amended, and as of March 31, 2025, was equal to 12.41% of the principal amount being repaid and continues to increase by 0.17% each month until maturity. The total new exit fees associated with the notes have been recorded as an original issue discount of $8.7 million and are being amortized over the remaining life of the note, which is assumed to be the maturity date. A corresponding liability for the new exit fees of $8.7 million was recorded for total accrued exit fees amount of $16.5 million which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. In addition, under the recent amendment, a new $5.0 million default fee will be payable on August 1, 2025, in the event all obligations under the note, including principal, any accrued and unpaid interest, and exit fees, are not repaid in full prior to the August 1, 2025, maturity date. The $5.0 million default fee will only be recognized in the event of a default on August 1, 2025.

As of March 31, 2025, the total carrying amount relating to the 20% note was $36.4 million, inclusive of $25.2 million of principal and capitalized interest, partially offset by $5.3 million of unamortized original issue discount, which are included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $16.5 million in total accrued exit fees which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on the note and the various amendments.

On February 20, 2025, Pansend closed on a new $3.5 million convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend, into shares of a new Series E Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date of the earlier of July 31, 2025, or a change in control of R2 Technologies, as defined in the note. The transaction is eliminated on consolidation. Refer to Note 15. Equity and Temporary Equity included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on R2 Technologies' convertible preferred stock and convertible notes.

Non-Operating Corporate

On March 6, 2025, we extended the maturity date of our Revolving Line of Credit with MSD from May 16, 2025, to August 1, 2025, with all other terms substantially unchanged. Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our Revolving Line of Credit with MSD.

Equity Method Investments

On January 17, 2025, MediBeacon received approval from the U.S. Food and Drug Administration ("FDA") for its Transdermal GFR Measurement System ("TGFR"). Pursuant to the terms of MediBeacon's convertible notes, upon the FDA approval, Pansend's convertible notes of $11.4 million and the related accrued interest of $1.5 million, together totaling $12.9 million, were converted into Series 3 Preferred Stock. In addition, pursuant to its amended commercial partnership with Huadong and, as a result of FDA approval, a $7.5 million milestone payment from Huadong Medicine Co. Ltd ("Huadong"), a publicly traded company on the Shenzhen Stock Exchange, to MediBeacon for MediBeacon preferred stock was received in the first quarter of 2025. As a result of these transactions, Pansend's ownership in MediBeacon decreased from 45.9% prior to the transactions to 44.7% subsequent to the transactions. On a fully diluted basis, Pansend's ownership in MediBeacon decreased from 40.1% to 39.7%. As a result of these transactions, Pansend recognized a step-up gain of $4.4 million in Other (expense) income, net in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2025, which increased Pansend's carrying amount of its investment in MediBeacon. Concurrently, Pansend recognized equity method losses of $5.9 million, consisting of the $4.4 million step-up gain and $1.5 million of interest from the conversion of the convertible notes, which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero.

Financial Presentation Background

In the below section within this Management’s Discussion and Analysis of Financial Condition and Results of Operations, we compare, pursuant to U.S. GAAP and SEC disclosure rules, the Company’s results of operations for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024.

Results of Operations

The following table summarizes our results of operations (in millions):

Revenue Three Months Ended March 31, 2025 2024 Increase / (Decrease)
Infrastructure $264.9 $307.9 $(43.0)
Life Sciences 3.1 1.0 2.1
Spectrum 6.2 6.3 (0.1)
Total revenue $274.2 $315.2 $(41.0)
Income (loss) from operations
Infrastructure $9.1 $9.3 $(0.2)
Life Sciences (3.0) (3.2) 0.2
Spectrum 0.2 0.2 —
Non-Operating Corporate (2.9) (3.5) 0.6
Total income from operations $3.4 $2.8 $0.6
Interest expense (20.2) (17.2) (3.0)
Loss from equity investees (5.9) (1.2) (4.7)
Other income (expense), net 4.0 (1.2) 5.2
Loss from operations before income taxes $(18.7) $(16.8) $(1.9)
Income tax expense (7.1) (3.3) (3.8)
Net loss $(25.8) $(20.1) $(5.7)
Net loss attributable to non-controlling interests and redeemable non-controlling interests 1.3 2.7 (1.4)
Net loss attributable to INNOVATE Corp. $(24.5) $(17.4) $(7.1)
Less: Preferred dividends 0.3 0.3 —
Net loss attributable to common stockholders and participating preferred stockholders $(24.8) $(17.7) $(7.1)

Revenue: Revenue for the three months ended March 31, 2025, decreased $41.0 million to $274.2 million from $315.2 million for the three months ended March 31, 2024. The decrease was primarily driven by our Infrastructure segment, which was partially offset by an increase at our Life Sciences segment. The decrease at our Infrastructure segment was primarily driven by the timing and size of projects at Banker Steel and the industrial maintenance and repair business, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which also had increased activity in the prior year on certain large commercial construction projects that have since been completed or are nearing completion in the current period. This was partially offset by an increase at DBMG's commercial structural steel fabrication and erection business as a result of an increase in project work. The increase at our Life Sciences segment was attributable to R2 Technologies, driven by an increase in unit sales of both Glacial fx and Glacial Rx systems and an increase in consumable sales in North America, as well as an increase in Glacial Spa unit sales, consumable sales and Glacial fx unit sales outside North America.

Income from operations: Income from operations for the three months ended March 31, 2025, increased $0.6 million to $3.4 million from $2.8 million for the three months ended March 31, 2024. The improvement was due to a decrease in other operating loss of $2.0 million and a decrease in selling, general and administrative ("SG&A") expenses of $1.7 million, which was partially offset by a net decrease in gross profit of $3.1 million. The net decrease in other operating loss was primarily driven by an unrepeated loss related to a plant closure at our Infrastructure segment in the comparable period. The overall decrease in SG&A was primarily driven by decreases in professional and consulting fees and compensation-related and travel expenses at our Infrastructure segment, which was partially offset by an increase in computer and software related costs in the current period at our Infrastructure segment and an increase in.selling costs at R2 Technologies due to an increase in unit sales. Partially offsetting the above improvements was a net decrease in gross profit, which was primarily driven by our Infrastructure segment due to timing and size of projects that have since been completed or are nearing completion in the current period, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which was partially offset by an increase in gross profit at our Life Sciences segment primarily driven by R2 Technologies as a result of an increase Glacial unit sales and consumable sales over the comparable period.

Interest expense: Interest expense for the three months ended March 31, 2025, increased $3.0 million to $20.2 million from $17.2 million for the three months ended March 31, 2024. The increase was primarily attributable to increases in exit fees and a higher outstanding principal balance at our Life Sciences segment as a result of the capitalization of unpaid interest into the principal balance subsequent to the comparable period, and, to a lesser extent our Spectrum segment. The increase in interest expense was partially offset by our Infrastructure and Non-Operating Corporate segments due to a net decrease in outstanding principal balances.

Loss from equity investees: Loss from equity investees for the three months ended March 31, 2025, increased $4.7 million to $5.9 million from $1.2 million for the three months ended March 31, 2024. The increase in loss was due to an increase in losses recognized from MediBeacon. During the three months ended March 31, 2025, as a result of the equity transactions that occurred upon FDA approval of MediBeacon's TGFR, Pansend's basis in MediBeacon increased by $5.9 million, consisting of a $4.4 million step-up gain and $1.5 million from the conversion of accrued interest on Pansend's convertible notes with MediBeacon, resulting in Pansend recognizing $5.9 million of equity method losses that were previously unrecognized. During the three months ended March 31, 2024, Pansend's basis in MediBeacon increased by $1.2 million due to the issuance of additional convertible note investments, resulting in Pansend recognizing $1.2 million of equity method losses that were previously unrecognized. As of both March 31, 2025 and 2024, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment. Refer to Note 6. Investments included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.

Other income (expense), net: Other income, net for the three months ended March 31, 2025, increased $5.2 million to income of $4.0 million from an expense of $1.2 million for the three months ended March 31, 2024. The increase was primarily driven by the $4.4 million step-up gain following MediBeacon's FDA approval in January 2025 and an unrepeated $2.2 million loss on debt extinguishment at R2 Technologies in the comparable period. These increases were partially offset by a decrease in foreign currency translation gains from our Infrastructure segment, and a legal settlement at our Non-Operating Corporate segment in the current period.

Income tax expense: Income tax expense for the three months ended March 31, 2025, increased $3.8 million to $7.1 million from $3.3 million for the three months ended March 31, 2024. The increase was primarily driven by the impact of projected pre-tax results on the annual effective tax rate and the limitations on the utilization of net operating losses ("NOL") by INNOVATE's U.S. consolidated group as a result of the Internal Revenue Code Section 382 and the Tax Cuts and Jobs Act's 80 percent limitation on NOLs incurred after 2017.

The Organization for Economic Cooperation and Development ("OECD") has announced an Inclusive Framework on Base Erosion and Profit Shifting including a Pillar Two Model to provide for a 15% global minimum tax on the earnings of multinational corporations with consolidated revenue over €750 million. Many jurisdictions have enacted Pillar Two legislation that started to become effective in 2024. The OECD, and its member countries, continue to release new guidance and legislation on Pillar Two. Based on current enacted laws, Pillar Two is not expected to materially impact our effective tax rate or cash flows in the next year. We will continue to evaluate the impact on our financial position as new legislation or guidance is introduced which could change our current assessment.

Segment Results of Operations

In the Company's Condensed Consolidated Financial Statements, other operating (income) loss includes: (i) (gain) loss on sale or disposal of assets; (ii) lease termination costs and (gains) losses on lease modifications; (iii) asset impairment expense; (iv) accretion of asset retirement obligations; and (v) Federal Communications Commission (the "FCC") reimbursements, as applicable. Each table summarizes the results of operations of our operating segments (in millions).

Infrastructure Segment

Three Months Ended March 31, 2025 2024 Increase / (Decrease)
Revenue $264.9 $307.9 $(43.0)
Cost of revenue 223.5 263.1 (39.6)
Selling, general and administrative 29.3 30.9 (1.6)
Depreciation and amortization 3.1 3.0 0.1
Other operating (income) loss (0.1) 1.6 (1.7)
Income from operations $9.1 $9.3 $(0.2)

Revenue: Revenue for the three months ended March 31, 2025, decreased $43.0 million to $264.9 million from $307.9 million for the three months ended March 31, 2024. The decrease was primarily driven by the timing and size of projects at Banker Steel and the industrial maintenance and repair business, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which also had increased activity in the prior year on certain large commercial construction projects that have since been completed or are nearing completion in the current period. This was partially offset by an increase at DBMG's commercial structural steel fabrication and erection business as a result of an increase in project work.

Cost of revenue: Cost of revenue for the three months ended March 31, 2025, decreased $39.6 million to $223.5 million from $263.1 million for the three months ended March 31, 2024. The decrease was primarily driven by the decrease in revenues at Banker Steel and the industrial maintenance and repair business from the timing of project activity on certain large commercial construction projects and decreases in costs as they wind down and near completion or were completed in the current period, which was partially offset by an increase in costs associated with DBMG's commercial structural steel fabrication and erection business as a result of an increase in project work.

Selling, general and administrative: Selling, general and administrative expense for the three months ended March 31, 2025, decreased $1.6 million to $29.3 million from $30.9 million for the three months ended March 31, 2024. The decrease was primarily driven by decreases in professional and consulting fees, compensation-related and travel expenses, which was partially offset by an increase in computer and software-related costs in the current period.

Other operating (income) loss: Other operating (income) loss for the three months ended March 31, 2025, improved by $1.7 million to income of $0.1 million from a loss of $1.6 million for the three months ended March 31, 2024. The improvement was primarily driven by an unrepeated loss related to a plant closure in the comparable period.

Life Sciences Segment

Three Months Ended March 31, 2025 2024 Increase / (Decrease)
Revenue $3.1 $1.0 $2.1
Cost of revenue 2.3 0.6 1.7
Selling, general and administrative 3.7 3.5 0.2
Depreciation and amortization 0.1 0.1 —
Loss from operations $(3.0) $(3.2) $0.2

Revenue: Revenue for the three months ended March 31, 2025, increased $2.1 million to $3.1 million from $1.0 million for the three months ended March 31, 2024. The increase in revenue was attributable to R2 Technologies, driven by an increase in unit sales of both Glacial fx and Glacial Rx systems and an increase in consumable sales in North America, as well as an increase in Glacial Spa unit sales, consumable sales and Glacial fx unit sales outside North America.

Cost of revenue: Cost of revenue for the three months ended March 31, 2025, increased $1.7 million to $2.3 million from $0.6 million for the three months ended March 31, 2024. The increase in cost of revenue was attributable to R2 Technologies, primarily driven by the increase in revenue from the additional system and consumables sales noted above, and, to a lesser extent, the related increases in warranty expenses, royalty expenses, and freight costs. The increase in cost of revenue was partially offset by changes in product mix sold as the Glacial fx and Glacial Spa systems have a lower production cost per system compared to the Glacial Rx.

Selling, general and administrative: Selling, general and administrative expense for the three months ended March 31, 2025, increased $0.2 million to $3.7 million from $3.5 million for the three months ended March 31, 2024. The increase was primarily driven by R2 Technologies as a result of an increase in selling costs due to an increase in unit sales.

Spectrum Segment

Three Months Ended March 31, 2025 2024 Increase / (Decrease)
Revenue $6.2 $6.3 $(0.1)
Cost of revenue 2.9 2.9 —
Selling, general and administrative 1.9 1.9 —
Depreciation and amortization 1.2 1.3 (0.1)
Income from operations $0.2 $0.2 $—

Revenue: Revenue for the three months ended March 31, 2025, decreased slightly by $0.1 million to $6.2 million from $6.3 million for the three months ended March 31, 2024. The decrease was primarily driven by the termination of a few networks and individual markets, which was partially offset by the launch of new networks subsequent to the comparable period.

Depreciation and amortization: Depreciation and amortization for the three months ended March 31, 2025, decreased slightly by $0.1 million to $1.2 million from $1.3 million for the three months ended March 31, 2024.

Non-Operating Corporate

Three Months Ended March 31, 2025 2024 Increase / (Decrease)
Selling, general and administrative $2.9 $3.2 $(0.3)
Other operating loss — 0.3 (0.3)
Loss from operations $(2.9) $(3.5) $0.6

Selling, general and administrative: Selling, general and administrative expenses for the three months ended March 31, 2025, decreased $0.3 million to $2.9 million from $3.2 million for the three months ended March 31, 2024, primarily driven by a decrease in legal fees due to legal matters settled subsequent to the comparable period, which was partially offset by an increase in share-based compensation expense related to the issuance of equity awards to our Interim-CEO, which awards had not yet been granted in the comparable period.

Other operating loss: Other operating loss for the three months ended March 31, 2025, decreased $0.3 million to zero from $0.3 million for the three months ended March 31, 2024. Other operating loss in the comparable period related to lease termination costs for two leases the Company exited in the comparable period.

Loss from Equity Investees

Three Months Ended March 31, 2025 2024 (Increase) / Decrease
Life Sciences $(5.9) $(1.2) $(4.7)
Loss from equity investees $(5.9) $(1.2) $(4.7)

Life Sciences: Loss from equity investees within our Life Sciences segment for the three months ended March 31, 2025, increased $4.7 million to $5.9 million from $1.2 million for the three months ended March 31, 2024. The increase in loss was due to an increase in losses recognized from MediBeacon. During the three months ended March 31, 2025, as a result of the equity transactions that occurred upon FDA approval of MediBeacon's TGFR, Pansend's basis in MediBeacon increased by $5.9 million, consisting of a $4.4 million step-up gain and $1.5 million from the conversion of accrued interest on Pansend's convertible notes with MediBeacon, resulting in Pansend recognizing $5.9 million of equity method losses that were previously unrecognized. During the three months ended March 31, 2024, Pansend's basis in MediBeacon increased by $1.2 million due to the issuance of additional convertible notes, resulting in Pansend recognizing $1.2 million of equity method losses that were previously unrecognized. As of both March 31, 2025 and 2024, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment.

Refer to Note 6. Investments included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.

Non-GAAP Financial Measures and Other Information

Adjusted EBITDA

Adjusted EBITDA is not a measurement recognized under U.S. GAAP. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-U.S. GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding: discontinued operations, if applicable; depreciation and amortization; other operating (income) loss, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, (gains) losses on lease modifications, asset impairment expense and FCC reimbursements; interest expense; other (income) expense, net; income tax expense (benefit); non-controlling interest; share-based compensation expense; and realignment and exit costs.

Adjusted EBITDA by segment is summarized as follows:

(in millions): Three Months Ended March 31, 2025 2024 Increase / (Decrease)
Infrastructure $16.7 $18.3 $(1.6)
Life Sciences (8.7) (4.2) (4.5)
Spectrum 1.4 1.6 (0.2)
Non-Operating Corporate (2.2) (2.9) 0.7
Other and Eliminations — — —
Adjusted EBITDA $7.2 $12.8 $(5.6)

The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp to Adjusted EBITDA for the three months ended March 31, 2025 and 2024:

(in millions)

Three Months Ended March 31, 2025 Infrastructure Life Sciences Spectrum Non-Operating Corporate Other and Eliminations INNOVATE
Net income (loss) attributable to INNOVATE Corp. $4.6 $(7.6) $(5.4) $(16.1) $— $(24.5)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:
Depreciation and amortization 3.1 0.1 1.2 — — 4.4
Depreciation and amortization (included in cost of revenue) 3.5 — — — — 3.5
Other operating income (0.1) — — — — (0.1)
Interest expense 2.1 4.5 3.7 9.9 — 20.2
Other (income) expense, net (0.3) (4.5) 2.2 (1.4) — (4.0)
Income tax expense 2.3 — — 4.8 — 7.1
Non-controlling interest 0.4 (1.4) (0.3) — — (1.3)
Share-based compensation expense — 0.2 — 0.6 — 0.8
Realignment and exit costs 1.1 — — — — 1.1
Adjusted EBITDA $16.7 $(8.7) $1.4 $(2.2) $— $7.2

(in millions)

Three Months Ended March 31, 2024 Infrastructure Life Sciences Spectrum Non-Operating Corporate Other and Eliminations INNOVATE
Net income (loss) attributable to INNOVATE Corp. $4.4 $(4.5) $(4.8) $(12.5) $— $(17.4)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:
Depreciation and amortization 3.0 0.1 1.3 — — 4.4
Depreciation and amortization (included in cost of revenue) 4.0 — — — — 4.0
Other operating loss 1.6 — — 0.3 — 1.9
Interest expense 2.7 0.9 3.4 10.2 — 17.2
Other (income) expense, net (0.8) 2.0 2.0 (2.0) — 1.2
Income tax expense 2.5 — — 0.8 — 3.3
Non-controlling interest 0.4 (2.8) (0.3) — — (2.7)
Share-based compensation expense — 0.1 — 0.3 — 0.4
Realignment and exit costs 0.5 — — — — 0.5
Adjusted EBITDA $18.3 $(4.2) $1.6 $(2.9) $— $12.8

Infrastructure: Net income from our Infrastructure segment for the three months ended March 31, 2025, increased $0.2 million to $4.6 million from $4.4 million for the three months ended March 31, 2024. Adjusted EBITDA from our Infrastructure segment for the three months ended March 31, 2025, decreased $1.6 million to $16.7 million from $18.3 million for the three months ended March 31, 2024. The decrease in Adjusted EBITDA was primarily driven by a decrease in revenue at both Banker Steel and the industrial maintenance and repair businesses due to timing of certain large commercial construction projects that have since been completed or are nearing completion in the current period. The decrease was partially offset by an increase in gross margins at the industrial maintenance and repair business and an increase in gross profit at DBMG's commercial structural steel fabrication and erection business due to an increase in project work, as well as a decrease in recurring SG&A, primarily as a result of decreases in professional and consulting fees and compensation-related and travel expenses, partially offset by an increase in computer and software-related costs in the current period.

Life Sciences: Net loss from our Life Sciences segment for the three months ended March 31, 2025, increased $3.1 million to $7.6 million from $4.5 million for the three months ended March 31, 2024. Adjusted EBITDA loss from our Life Sciences segment for the three months ended March 31, 2025, increased $4.5 million to $8.7 million from $4.2 million for the three months ended March 31, 2024. The increase in Adjusted EBITDA loss was primarily due to an increase in equity method losses recognized from MediBeacon, as discussed in the Loss from Equity Investees section above, and an increase in selling costs at R2 Technologies due to the increase in unit sales. The increase in Adjusted EBITDA loss was partially offset by an increase in gross profit at R2 Technologies, driven by an increase in unit sales of both the Glacial fx and Glacial Rx systems and an increase in consumable sales in North America, as well as an increase in Glacial Spa unit sales, consumable sales and Glacial fx unit sales outside North America.

Spectrum: Net loss from our Spectrum segment for the three months ended March 31, 2025, increased $0.6 million to $5.4 million from $4.8 million for the three months ended March 31, 2024. Adjusted EBITDA from our Spectrum segment for the three months ended March 31, 2025, decreased slightly by $0.2 million to $1.4 million from $1.6 million for the three months ended March 31, 2024. The decrease in Adjusted EBITDA was primarily driven by the termination of a few networks and individual markets, which was partially offset by the launch of new networks subsequent to the comparable period.

Non-Operating Corporate: Net loss from our Non-Operating Corporate segment for the three months ended March 31, 2025, increased $3.6 million to $16.1 million from $12.5 million for the three months ended March 31, 2024. Adjusted EBITDA loss from our Non-Operating Corporate segment for the three months ended March 31, 2025, decreased $0.7 million to $2.2 million from $2.9 million for the three months ended March 31, 2024. The decrease in Adjusted EBITDA loss was primarily driven by a decrease in legal fees due to legal matters settled subsequent to the comparable period.

Backlog

Backlog is our estimate of the U.S. dollar amount of future revenues we expect to realize as a result of performing work on projects in backlog. Projects in backlog consist of awarded contracts, letters of intent, notices to proceed, change orders, and purchase orders obtained. Backlog increases as contract commitments are obtained, decreases as revenues are recognized and increases or decreases to reflect modifications in the work to be performed under the contracts. Backlog is converted to sales in future periods as work is performed or projects are completed. Backlog can be significantly affected by the receipt or loss of individual contracts.

Infrastructure Segment

As of March 31, 2025, DBMG's backlog was $1,369.9 million, consisting of $939.0 million under contracts or purchase orders and $430.9 million under letters of intent or notices to proceed. Approximately $714.6 million, representing 52.2% of DBMG’s backlog as of March 31, 2025, was attributable to five contracts, letters of intent, notices to proceed or purchase orders. If one or more of these projects terminate or reduce their scope, DBMG’s backlog could decrease substantially. DBMG includes an additional $12.1 million in its backlog that is not included in the remaining unsatisfied performance obligations disclosed in Note 3. Revenue and Contracts in Process. This additional backlog includes commitments under master service agreements that are estimated amounts of work to be performed based on customer communications, historic performance and knowledge of our customers' intentions.

Liquidity and Capital Resources

Short- and Long-Term Liquidity Considerations and Risks

Our Non-Operating Corporate segment's liquidity needs are primarily for interest payments on its 2026 Senior Secured Notes, 2026 Convertible Notes, Revolving Line of Credit, CGIC Unsecured Note, and dividend payments on its Series A-3 and Series A-4 Preferred Stock and recurring operational expenses.

On a consolidated basis, as of March 31, 2025, we had $33.3 million of cash and cash equivalents, excluding restricted cash, compared to $48.8 million as of December 31, 2024. On a stand-alone basis, as of March 31, 2025, our Non-Operating Corporate segment had cash and cash equivalents, excluding restricted cash, of $3.0 million and $2.3 million of marketable securities, as compared to cash and cash equivalents, excluding restricted cash, of $13.8 million and $1.8 million of marketable securities as of December 31, 2024.

Our subsidiaries' principal liquidity requirements arise from cash used in operating activities, debt service, and capital expenditures, including purchases of steel construction equipment, OTA broadcast station equipment, development of back-office systems, operating costs and expenses, and income taxes.

As of March 31, 2025, we had $672.0 million of principal indebtedness on a consolidated basis compared to $668.3 million as of December 31, 2024, a net increase of $3.7 million, which was primarily due to a $2.5 million net increase in debt at our Infrastructure segment, and an increase at our Life Sciences segment due to the capitalization of $1.2 million of unpaid accrued interest at R2 Technologies into their outstanding principal balance.

On a stand-alone basis, our Non-Operating Corporate segment indebtedness was $429.9 million in principal amount as of both March 31, 2025 and December 31, 2024. The March 31, 2025, indebtedness balance consists of the $330.0 million aggregate principal amount of 2026 Senior Secured Notes, $48.9 million aggregate principal amount of 2026 Convertible Notes (which excludes the $2.9 million 2026 Convertible Notes repurchased in 2024 and retired by the Company in 2025), $31.0 million principal amount of the CGIC Unsecured Note and $20.0 million aggregate principal amount drawn on our Revolving Line of Credit. Our Non-Operating Corporate segment is required to make semi-annual interest payments on the 2026 Senior Secured Notes and 2026 Convertible Notes on February 1st and August 1st of each year, quarterly interest payments on the Revolving Line of Credit, and monthly interest payments on the CGIC Unsecured Note. As described below, the interest rate on the CGIC Unsecured Note increased from 9.0% per annum to 16.0% per annum on May 9, 2024, and will increase from 16.0% per annum to 32.0% per annum on May 9, 2025.

We are required to make dividend payments on our outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock on January 15th, April 15th, July 15th, and October 15th of each year.

Our Non-Operating Corporate segment received $15.6 million in net tax sharing payments from our Infrastructure segment for the three months ended March 31, 2025.

We have financed our growth and operations to date, and expect to finance our future growth and operations, through public offerings and private placements of debt and equity securities, credit facilities, vendor financing, finance lease financing and other financing arrangements, as well as cash generated from the operations of our subsidiaries. In the future, we may also choose to sell assets or certain investments to generate cash.

Rights Offering and Concurrent Private Placement

On March 8, 2024, the Company commenced a rights offering ("Rights Offering"), in which each holder of the Company’s common stock, Series A-3 Convertible Participating Preferred Stock, Series A-4 Convertible Participating Preferred Stock and the 2026 Convertible Notes as of March 6, 2024 (the “rights offering record date”), were granted rights to purchase common stock. In connection with the Rights Offering, the Company entered into an Investment Agreement with Lancer Capital (the "Investment Agreement"), pursuant to which Lancer Capital agreed to purchase up to $19.0 million of Series C Preferred Stock as a backstop to the Rights Offering (the "Backstop Commitment") and to purchase $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement"). Lancer Capital is an investment fund led by Avram A. Glazer, the Chairman of the Board and the Company’s largest stockholder. As the Rights Offering had not yet settled by March 28, 2024, in accordance with the Investment Agreement, Lancer Capital purchased $25.0 million of Series C Preferred Stock, referred to as the "equity advance." On April 24, 2024, the Company completed and closed on the Rights Offering and issued a total of 530,611 shares of common stock (5,306,105 shares of common stock on a pre Reverse Stock Split (see below) basis) for $3.7 million. In addition, Lancer Capital purchased an additional approximately 6,286 Series C Preferred Stock for $6.3 million under the Backstop Commitment. In total, the Company received $35.0 million in aggregate gross proceeds related to the Rights Offering and Concurrent Private Placement and incurred $1.8 million in dealer manager fees and other related costs which were capitalized into Additional paid in capital ("APIC"). On June 18, 2024, the Company's shareholders approved the conversion of the Series C Preferred Stock into common stock, and approximately 31,286 shares of Series C Preferred Stock, which were held by Lancer Capital, were converted into 4,469,390 shares of common stock (44,693,895 shares of common stock on a pre Reverse Stock Split basis), and there were no shares of the Series C Preferred Stock outstanding subsequent to their conversion into the Company's common stock.

INNOVATE utilized the net proceeds from the Rights Offering and Concurrent Private Placement for general corporate purposes, including debt service and for working capital. As a result of the closing of the Rights Offering and Concurrent Private Placement, a mandatory prepayment was required on the CGIC Unsecured Note, and on April 26, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note. See Note 15. Equity and Temporary Equity for additional information.

Going Concern

The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

The principal conditions leading to this conclusion are the upcoming maturities of current debt at our Non-Operating Corporate segment and the Company's subsidiaries as well as from certain cross-default provisions in the Company's Senior Secured Notes. Based on these conditions, the Company may not be able to meet its obligations at maturity and comply with certain cross-default provisions under the Senior Secured Notes over the next twelve months.

Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The potential inability to refinance or extend the maturity of the aforementioned current debt, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.

The Company plans to alleviate these conditions through various initiatives it is currently exploring, including potentially refinancing the debt at our Non-Operating Corporate segment and its subsidiaries, pursuing asset sales, and raising additional capital. However, there can be no assurance that the Company will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance its existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with the Company’s debt covenants or other possible events of default. Further, there can be no assurance that the Company will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.

The Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.

While the Company has noted the conditions above regarding its ability to continue as a going concern, it is important to note that the Company’s largest subsidiary, DBMG, is operationally profitable, continues to maintain a strong financial position and remains in good standing with its lenders. Under INNOVATE’s Senior Secured Notes Indenture, DBMG is a restricted subsidiary, not a guarantor, and INNOVATE’s equity interests in DBMG are pledged as collateral.

Capital Expenditures

Capital expenditures are set forth in the table below (in millions):

Three Months Ended March 31, 2025 2024
Infrastructure $4.1 $5.2
Life Sciences 0.1 0.1
Spectrum 0.5 0.3
Total $4.7 $5.6

Indebtedness

Non-Operating Corporate

2026 Senior Secured Notes

On February 1, 2021, our Non-Operating Corporate segment repaid the senior secured notes that were due in 2021 and issued $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "2026 Senior Secured Notes"). The 2026 Senior Secured Notes mature on February 1, 2026, and accrue interest at a rate of 8.50% per year, which interest is paid semi-annually on February 1st and August 1st of each year. If the Company sells certain assets and the net cash proceeds from all applicable asset sales exceed $50.0 million since the issue date of the 2026 Senior Secured Notes, the Company may be required in certain circumstances to make an offer to purchase the notes with the net cash proceeds from such an asset sale in excess of such $50.0 million threshold at a price in cash equal to 101% of the principal amount thereof, together with accrued and unpaid interest, if any, to the date of purchase.

For additional information on the terms and conditions of the 2026 Senior Secured Notes, including guarantees, ranking and collateral, refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025.

2026 Convertible Notes

The original $51.8 million aggregate principal amount of 7.50% convertible notes (the "2026 Convertible Notes") were issued under a separate indenture dated February 1, 2021, between the Company and U.S. Bank, as trustee (the "Convertible Indenture"). In July 2024, we repurchased $2.9 million principal amount of our 2026 Convertible Notes at a market discount for $1.1 million, which was inclusive of accrued interest of $0.1 million. As of March 31, 2025, we had $48.9 million principal amount of 2026 Convertible Notes outstanding. The 2026 Convertible Notes mature on August 1, 2026, unless earlier converted, redeemed or purchased. The 2026 Convertible Notes accrue interest at a rate of 7.5% per year, which interest is paid semi-annually on February 1st and August 1st of each year.

For additional information on the terms and conditions of the 2026 Convertible Notes, including optional redemption, conversion rights guarantees, ranking and collateral, refer to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025.

Our debt contains customary events of default which could, subject to certain conditions, cause the 2026 Senior Secured Notes and the 2026 Convertible Notes to become immediately due and payable.

Revolving Line of Credit

We have a revolving credit agreement with MSD PCOF Partners IX, LLC ("MSD") which has a maximum commitment of $20.0 million ("Revolving Line of Credit"), of which $20.0 million had been drawn as of March 31, 2025. Interest on loans under the Revolving Line of Credit accrues at SOFR plus 5.75% and is payable quarterly. The Revolving Line of Credit also includes a commitment fee at a per annum rate of 1.0% calculated based off the actual daily amount of unused availability under the Revolving Line of Credit with MSD. The maturity date of the Revolving Line of Credit, as amended on March 6, 2025, is August 1, 2025. The amount outstanding under the Revolving Line of Credit is subject to mandatory prepayment from the net cash proceeds from certain asset sales in excess of $10.0 million.

For additional information on the terms and conditions of the Revolving Line of Credit, including guarantees and ranking and collateral, refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025.

CGIC Unsecured Note

On May 9, 2023, in connection with the redemption of the DBMGi Series A Preferred Stock, the Company issued a subordinated unsecured promissory note to CGIC in the principal amount of $35.1 million (the "CGIC Unsecured Note"). The CGIC Unsecured Note is due February 28, 2026, and bore interest at 9.0% per annum through May 8, 2024, bears interest at 16.0% per annum from May 9, 2024, to May 8, 2025, and 32.0% per annum thereafter. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3.0 million or 12.5% of the net proceeds from certain equity sales. Other covenants in the CGIC Unsecured Note are generally consistent with the Company's Indenture governing the 8.50% Senior Secured Notes due 2026, dated as of February 1, 2021, by and among the Company, the guarantors party thereto and U.S. Bank National Association. As a result of the closing of the Rights Offering, on April 24, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note on April 26, 2024.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and to Note 16. Equity and Temporary Equity and to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional information.

Infrastructure

As of March 31, 2025, our Infrastructure segment has aggregate principal outstanding debt, including obligations under finance leases, of $147.2 million.

DBMG has a $135.0 million Revolving Line with UMB that bears interest at a prime rate minus a spread with an interest rate floor of 4.25%. As of March 31, 2025, the outstanding balance was $50.0 million. The effective interest rate on the Revolving Line with UMB was 6.72% as of March 31, 2025. The Revolving Line with UMB matures on August 15, 2025, and interest is paid monthly. The Revolving Line with UMB also includes a commitment fee equal to 0.25% per annum times the average daily unused availability under the line.

DBMG also has a $72.8 million term loan due 2026 (the "3.25% UMB Term Loan"), which expires May 31, 2026, and bears interest at an annual rate of 3.25% with an effective interest rate of 3.3%. Principal payments and interest are paid monthly. On June 28, 2024, DBM and UMB entered into the Third Amendment to the UMB Credit Agreement. The amendment added an incremental separate term loan of $25.0 million to the existing credit facility, of which $24.2 million is outstanding as of March 31, 2025. The incremental term loan bears the same interest rate as the Revolving Line with UMB and has the same maturity date as the initial 3.25% UMB Term Loan.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional details regarding the indebtedness of our Infrastructure segment.

Life Sciences

As of March 31, 2025, our Life Sciences segment has aggregate principal outstanding debt of $25.2 million.

R2 Technologies has a short-term note with Lancer Capital. Interest on the note, as amended, is payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest is capitalized monthly into the principal balance. During the first quarter of 2025, with an effective date of December 31, 2024, the maturity date of the note was extended to August 1, 2025, and another additional exit fee of $1.0 million was incurred under the amendment, which continues to increase by $1.0 million each month until maturity. The base exit fee, as amended, and as of March 31, 2025, was equal to 12.41% of the principal amount being repaid and continues to increase by 0.17% each month until maturity. The total new exit fees associated with the notes have been recorded as an original issue discount of $8.7 million and are being amortized over the remaining life of the note, which is assumed to be the maturity date. A corresponding liability for the new exit fees of $8.7 million was recorded for total accrued exit fees amount of $16.5 million which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. In addition, under the recent amendment, a new $5.0 million default fee will be payable on August 1, 2025, in the event all obligations under the note, including principal, any accrued and unpaid interest, and exit fees, are not repaid in full prior to the August 1, 2025, maturity date. The $5.0 million default fee will only be recognized in the event of a default on August 1, 2025.

As of March 31, 2025, the total carrying amount relating to the 20% note was $36.4 million, inclusive of $25.2 million of principal and capitalized interest, partially offset by $5.3 million of unamortized original issue discount, which are included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, and $16.5 million in total accrued exit fees which are included within Accrued liabilities in the Condensed Consolidated Balance Sheet.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional information on the note and the various amendments.

On February 20, 2025, Pansend closed on a new $3.5 million convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend, into shares of a new Series E Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date of the earlier of July 31, 2025, or a change in control of R2 Technologies, as defined in the note. The transaction is eliminated on consolidation. Refer to Note 15. Equity and Temporary Equity included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on R2 Technologies' convertible preferred stock and convertible notes.

Spectrum

As of March 31, 2025, our Spectrum segment has aggregate principal outstanding debt of $69.7 million, consisting of 8.50% and 11.45% Notes. Interest is capitalized and payable upon maturity of the notes. The maturity date, as amended, of Spectrum's 8.50% and 11.45% Notes, is August 15, 2025.

The exit fees associated with the notes, which are payable on the earlier of maturity or repayment of the principal, were recorded as original issue discount and are being amortized over the remaining life of the notes, which is assumed to be the maturity date. A corresponding liability of $15.9 million is reflected within Accrued Liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. As of March 31, 2025 and December 31, 2024, the weighted-average effective interest rates on the notes, as amended, was 22.9% and 22.8%, respectively.

During November 2023, concurrently with Broadcasting's execution of the Ninth Amendment to Secured Notes, which among other things extended the maturity of the notes, INNOVATE entered into a related side letter with the lenders, whereby INNOVATE agreed to utilize proceeds from the sale of certain of its existing operations, as allowable under the Company's current agreements and indentures and after all other required payments have been made, for repayment of a portion of our Spectrum segment's Senior Secured Notes. Assuming there are sufficient proceeds remaining after such repayment, an additional $2.0 million is payable for payments made after November 9, 2024, and in exchange for the additional fee, the institutional investors will return their equity interests in HC2 Broadcasting Holdings, Inc. and their equity interests in DTV America.

Refer to Note 11. Debt Obligations included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, and Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2024 Annual Report on Form 10-K, which was filed with the SEC on March 31, 2025, for additional information.

Restrictive Covenants

The indenture governing the 2026 Senior Secured Notes dated February 1, 2021, by and among INNOVATE, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee (the "Secured Indenture"), contains certain affirmative and negative covenants limiting, among other things, the ability of the Company, and, in certain cases, the Company’s subsidiaries, to incur additional indebtedness; create liens; engage in sale-leaseback transactions; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. These covenants are subject to a number of important exceptions and qualifications.

The Company is also required to comply with certain financial maintenance covenants, which are similarly subject to a number of important exceptions and qualifications. These covenants include maintenance of (1) liquidity and (2) collateral coverage.

The maintenance of liquidity covenant provides that the Company will not permit the aggregate amount of (i) all unrestricted cash and Cash Equivalents of the Company and the Subsidiary Guarantors, (ii) amounts available for drawing under revolving credit facilities and undrawn letters of credit of the Company and the Subsidiary Guarantors and (iii) dividends, distributions or payments that are immediately available to be paid to the Company by any of its Restricted Subsidiaries to be less than the Company’s obligation to pay interest for the next six months on the 2026 Senior Secured Notes and all other Debt, including Convertible Series A-3 and Series A-4 Preferred Stock mandatory cash dividends or any other mandatory cash pay Series A-3 and Series A-4 Preferred Stock but excluding any obligation to pay interest on Series A-3 and Series A-4 Preferred Stock or any other mandatory cash payments on Series A-3 and Series A-4 Preferred Stock which, in each case, may be paid by accretion or in-kind in accordance with its terms of the Company and its Subsidiary Guarantors. As of March 31, 2025, the Company was in compliance with this covenant.

The maintenance of collateral coverage provides that the certain subsidiaries' Collateral Coverage Ratio (as defined in the Secured Indenture as the ratio of (i) the Loan Collateral to (ii) Consolidated Secured Debt (each as defined therein)) calculated on a pro forma basis as of the last day of each fiscal quarter may not be less than 1.50 to 1.00. As of March 31, 2025, the Company was in compliance with this covenant.

The instruments governing the Company’s Series A-3 Preferred Stock and Series A-4 Preferred Stock also limit the Company’s and its subsidiaries ability to take certain actions, including, among other things, to incur additional indebtedness; issue additional Series A-3 Preferred Stock and Series A-4 Preferred Stock; engage in transactions with affiliates; and make certain restricted payments. These limitations are subject to a number of important exceptions and qualifications.

The Company has conducted its operations in a manner that has resulted in compliance with the Secured Indenture; however, compliance with certain financial covenants for future periods may depend on the Company or one or more of the Company’s subsidiaries undertaking one or more non-operational transactions, such as the management of operating cash outflows, a monetization of assets, a debt incurrence or refinancing, the raising of equity capital, or similar transactions. If the Company is unable to remain in compliance and does not make alternate arrangements, an event of default would occur under the Company’s Secured Indenture which, among other remedies, could result in the outstanding obligations under the indenture becoming immediately due and payable and permitting the exercise of remedies with respect to the collateral. There is no assurance the Company will be able to complete any non-operational transaction it may undertake to maintain compliance with covenants under the Secured Indenture or, even if the Company completes any such transaction, that it will be able to maintain compliance for any subsequent period.

The UMB term loans and Revolving Line with UMB associated with our Infrastructure segment contain customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio covenant, as defined in the agreement.

As of March 31, 2025, we were in compliance with the covenants of our debt agreements.

Summary of Consolidated Cash Flows

The below table summarizes the cash provided by or used in our activities (in millions):

Three Months Ended March 31, 2025 2024 Increase / (Decrease)
Cash used in operating activities $(14.1) $(25.4) $11.3
Cash used in investing activities (3.9) (3.3) (0.6)
Cash provided by (used in) financing activities 2.4 (12.9) 15.3
Effects of exchange rate changes on cash, cash equivalents and restricted cash 0.2 (0.8) 1.0
Net decrease in cash and cash equivalents, including restricted cash $(15.4) $(42.4) $27.0

Operating Activities

Cash used in operating activities was $14.1 million for the three months ended March 31, 2025, as compared to $25.4 million for the three months ended March 31, 2024, a decrease in cash used in operating activities of $11.3 million. Cash flows from operations are primarily influenced by changes in the timing of demand for services and by operating margins, but can also be affected by working capital needs associated with our operations. For the three months ended March 31, 2025, the decrease in cash used in operating activities was primarily driven by a decrease in working capital outflows at our Infrastructure segment, partially offset by an increase in cash used in operating activities at our Non-Operating Corporate segment. The decrease in working capital outflows at our Infrastructure segment was primarily due to normal business fluctuations in accounts receivable, accounts payable, contract-related assets and liabilities, and other accrued liabilities due to the timing of regular billing and collection activities and changes in contract assets and liabilities due to ordinary course business project activity. Our Non-Operating Corporate segment's increase in cash used in operating activities was primarily due to an increase in net loss and increases in working capital outflows primarily for taxes and interest.

Investing Activities

Cash used in investing activities was $3.9 million for the three months ended March 31, 2025, as compared to $3.3 million for the three months ended March 31, 2024, an increase in cash used in investing activities of $0.6 million. Capital expenditures totaled $4.7 million, or $3.6 million net of proceeds from disposals, for the three months ended March 31, 2025, as compared to $5.6 million, or $2.5 million net of proceeds from disposals, for the three months ended March 31, 2024, for an increase in cash used in investing activities of $1.1 million. The increase was primarily driven by our Infrastructure segment, which had more PP&E sales in the comparable period due to a plant closure in the first quarter of 2024, partially offset by fewer PP&E additions in the current period, and a slight increase in PP&E additions at our Spectrum segment in the current period. In addition, our Corporate segment purchased marketable investments for $0.3 million during the three months ended March 31, 2025, and other investing activities for the comparable period included unrepeated proceeds of $0.4 million which primarily related to a note receivable at our Life Sciences segment. These increases in cash used in investing activities were partially offset by unrepeated loans made by our Life Sciences segment to MediBeacon of $1.2 million in the comparable period.

Financing Activities

Cash provided by financing activities was $2.4 million for the three months ended March 31, 2025, as compared to cash used in financing activities of $12.9 million for the three months ended March 31, 2024, an improvement in financing cash flows of $15.3 million. The improvement was primarily driven by our Infrastructure segment's payment activity on its Revolving Line with UMB, which had a $35.0 million net decrease in revolving credit line outflows due to payments made in the comparable period to reduce the outstanding balance. For the three months ended March 31, 2025, principal payments for other debt obligations at our Infrastructure segment totaled $2.2 million, as compared to $7.6 million in the comparable period, a decrease of $5.4 million. These improvements were partially offset by our Non-Operating Corporate segment, which had completed the issuance of the $25.0 million Convertible Series C Preferred Stock in the comparable period related to the 2024 Rights Offering and Concurrent Private Placement.

Infrastructure

Cash Flows

Cash flows from operating activities are the principal source of cash used to fund DBMG’s operating expenses, interest payments on debt, and capital expenditures. DBMG's short-term cash needs are primarily for working capital to support operations including receivables, inventories, and other costs incurred in performing on its contracts. DBMG attempts to structure the payment arrangements under its contracts to match costs incurred under the project. To the extent it is able to bill in advance of costs incurred, DBMG generates working capital through billings in excess of costs and recognized earnings on uncompleted contracts. DBMG relies on its credit facilities to meet its working capital needs. DBMG believes that its available funds, cash generated by operating activities and funds available under its bank credit facilities will be adequate to meet all funding requirements for its operating expenses, working capital needs, interest payments on debt and capital expenditures for the foreseeable future. However, DBMG may expand its operations through future acquisitions and may require additional equity or debt financing.

DBMG is required to make monthly interest payments on all of its debt. Based upon the March 31, 2025 debt balance, DBMG anticipates that its interest payments will be approximately $1.5 million for each quarter of 2025.

New Accounting Pronouncements

For information on new accounting pronouncements, refer to Note 2. Summary of Significant Accounting Policies included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Critical Accounting Estimates

There have been no material changes in the Company’s critical accounting policies during the period ended March 31, 2025. For information about critical accounting policies and estimates, refer to “Critical Accounting Estimates” under Item 7 of our 2024 Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025.

Related Party Transactions

For a discussion of our Related Party Transactions, refer to Note 16. Related Parties included in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains or incorporates a number of "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based on current expectations, and are not strictly historical statements. In some cases, you can identify forward-looking statements by terminology such as "if," "may," "should," "believe," "anticipate," "future," "forward," "potential," "estimate," "opportunity," "goal," "objective," "growth," "outcome," "could," "expect," "intend," "plan," "strategy," "provide," "commitment," "result," "seek," "pursue," "ongoing," "include" or in the negative of such terms or comparable terminology. These forward-looking statements inherently involve certain risks and uncertainties and are not guarantees of performance, results, or the creation of stockholder value, although they are based on our current plans or assessments which we believe to be reasonable as of the date hereof.

Factors that could cause actual results, events and developments to differ include, without limitation: the ability of our subsidiaries (including, target businesses following their acquisition) to generate sufficient net income and cash flows to make upstream cash distributions, capital market conditions, our and our subsidiaries’ ability to identify any suitable future acquisition opportunities, efficiencies/cost avoidance, cost savings, income and margins, growth, economies of scale, combined operations, future economic performance, conditions to, and the timetable for, completing future acquisitions and dispositions and the successful integration of acquisitions, litigation, potential and contingent liabilities, management’s plans, changes in regulations and taxes.

We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

Forward-looking statements are not guarantees of performance. You should understand that the following important factors, in addition to those discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025, and the documents incorporated herein by reference, could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements. You should also understand that many factors described under one heading below may apply to more than one section in which we have grouped them for the purpose of this presentation. As a result, you should consider all of the following factors, together with all of the other information presented herein, in evaluating our business and that of our subsidiaries.

INNOVATE Corp. and Subsidiaries

Our actual results or other outcomes may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

  • our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations;
  • substantial doubt about our ability to continue operating as a going concern;
  • the impact on our business and financial condition of our substantial indebtedness and the significant additional indebtedness and other financing obligations we may incur;
  • the impact of covenants in the Indenture governing INNOVATE’s 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Unsecured Note and Revolving Line of Credit, the Certificates of Designation governing INNOVATE’s Series A-3 Preferred Stock and Series A-4 Preferred Stock and all other subsidiary debt obligations as summarized in Note 11. Debt Obligations to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC March 31, 2025, and future financing agreements on our ability to operate our business and finance our pursuit of acquisition opportunities;
  • our possible inability to generate sufficient liquidity, margins, earnings per share, cash flow and working capital from our operating segments;
  • our dependence on certain key personnel including the passing in 2023 of Mr. Barr, our former CEO, President and Director and the successful transition of his management responsibilities;
  • bank failures or other similar events that could adversely affect our and our customers' and vendors' liquidity and financial performance;
  • our possible inability to hire and retain qualified executive management, sales, technical and other personnel;
  • the potential for, and our ability to, remediate future material weaknesses in our internal controls over financial reporting;
  • changes in market conditions, including from political regulatory or market uncertainty, changes in foreign exchange rates, interest rates or inflation, supply chain disruptions, labor shortages and increases in overall price levels, including in transportation costs;
  • the uncertain effects of U.S. and foreign government actions affecting international trade and economic policy, including changes in volatility in tariffs and trade policies and retaliatory actions, on credit markets, customers, and customer retention, and demand for our products and services;
  • increased competition in the markets in which our operating segments conduct their businesses;
  • limitations on our ability to successfully identify any strategic acquisitions or business opportunities and to compete for these opportunities with others who have greater resources;
  • our ability to effectively increase the size of our organization, if needed, and manage our growth;
  • the impact of expending significant resources in considering acquisition targets or business opportunities that are not consummated;
  • our expectations and timing with respect to our ordinary course acquisition activity and whether such acquisitions are accretive or dilutive to stockholders;
  • the effect any interests our officers, directors, stockholders and their respective affiliates may have in certain transactions in which we are involved;
  • uncertain global economic conditions in the markets in which our operating segments conduct their businesses;
  • the effects related to or resulting from ongoing and recent geopolitical events, such as the political unrest and military conflicts in the Middle East, Russia and Ukraine, including the imposition of additional sanctions and export controls, as well as the broader impact to financial markets and the global macroeconomic and geopolitical environment;
  • the impact of catastrophic events, including natural disasters, pandemic illness and the outbreak of war, or acts of terrorism;
  • potential impacts on our business resulting from climate change, greenhouse gas regulations, and the impact of climate change-related changes in the frequency and severity of weather patterns;
  • the impact of additional material charges associated with our oversight of acquired or target businesses and the integration of our financial reporting;
  • tax consequences associated with our acquisition, holding and disposition of target companies and assets;
  • our ability to remain in compliance with the listing standards of the NYSE;
  • the Reverse Stock Split may not result in a sustained increase in the per share price of our common stock;
  • the ability of our operating segments to attract and retain customers;
  • our expectations regarding the timing, extent and effectiveness of our cost reduction initiatives and management’s ability to moderate or control discretionary spending;
  • management’s plans, goals, forecasts, expectations, guidance, objectives, strategies and timing for future operations, acquisitions, synergies, asset dispositions, fixed asset and goodwill impairment charges, tax and withholding expense, selling, general and administrative expenses, product plans, performance and results;
  • management’s assessment of market factors and competitive developments, including pricing actions and regulatory rulings;
  • our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses, that we may make in the future and the effect of any such dispositions or sales on our results of operations;
  • the possibility of indemnification claims arising out of divestitures of businesses; and
  • our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all.

Infrastructure / DBM Global Inc.

Our actual results or other outcomes of DBMG, and, thus, our Infrastructure segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

  • adverse impacts from weather affecting DBMG’s performance and timeliness of completion of projects, which could lead to increased costs and affect the quality, costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
  • cost overruns on fixed-price or similar contracts or failure to receive timely or proper payments on cost-reimbursable contracts, whether as a result of improper estimates, performance, disputes, or otherwise;
  • uncertain timing and funding of new contract awards, as well as project cancellations;
  • potential impediments and limitations on our ability to complete ordinary course acquisitions in anticipated time frames or at all;
  • changes in the costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
  • changes in economic conditions, including from the impact of inflationary pressures and changes in interest rates;
  • adverse outcomes of pending claims or litigation or the possibility of new claims or litigation, and the potential effect of such claims or litigation on DBMG’s business, financial condition, results of operations or cash flow;
  • risks associated with labor productivity, including performance of subcontractors that DBMG hires to complete projects;
  • its ability to realize cost savings from expected performance of contracts, whether as a result of improper estimates, performance, or otherwise;
  • its ability to settle or negotiate unapproved change orders and claims;
  • fluctuating revenue resulting from a number of factors, including the cyclical nature of the individual markets in which our customers operate;
  • our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all; and
  • lack of necessary liquidity to provide bid, performance, advance payment and retention bonds, guarantees, or letters of credit securing DBMG’s obligations under bids and contracts or to finance expenditures prior to the receipt of payment for the performance of contracts.

Life Sciences / Pansend Life Sciences, LLC

Our actual results or other outcomes of Pansend Life Sciences, LLC, and, thus, our Life Sciences segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

  • our Life Sciences segment’s ability to invest in development stage companies;
  • our Life Sciences segment’s ability to develop products and treatments related to its portfolio companies;
  • medical advances in healthcare and biotechnology;
  • governmental regulation in the healthcare industry; and
  • our Life Sciences segment's possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all.

Spectrum / HC2 Broadcasting Holdings Inc.

Our actual results or other outcomes of Broadcasting, and, thus, our Spectrum segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

  • our Spectrum segment’s ability to operate in highly competitive markets and maintain market share;
  • our Spectrum segment’s ability to effectively implement its business strategy or be successful in the operation of its business;
  • our Spectrum segment's possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all;
  • new and growing sources of competition in the broadcasting industry; and
  • FCC regulation of the television broadcasting industry.

We caution the reader that undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this document. Neither we nor any of our subsidiaries undertake any duty or responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this document or to reflect actual outcomes, except as required by applicable law.

Controls and procedures

As filed, 1,621 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended (the "Exchange Act") as of the end of the period covered by this report. Based on this evaluation, our Interim Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2025, our disclosure controls and procedures were effective. Disclosure controls and procedures mean our controls and other procedures that are designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 311 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in our risk factors from those disclosed in Part 1, Item 1A of our Fiscal Year 2024 Form 10-K, which was filed with the SEC on March 31, 2025. See "Risk Factors" in Item 1A of Part I of such Fiscal Year 2024 Form 10-K for a complete description of the material risks we face.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-01-01 to 2025-03-31$274.2mus-gaap:Revenues
Cost of revenue3 months2025-01-01 to 2025-03-31$228.7mus-gaap:CostOfRevenue
Gross profit3 months2025-01-01 to 2025-03-31$45.5mus-gaap:GrossProfit
Selling, general and administrative3 months2025-01-01 to 2025-03-31$37.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-01-01 to 2025-03-31$3.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-01-01 to 2025-03-31$20.2mus-gaap:InterestExpenseNonoperating
Income tax3 months2025-01-01 to 2025-03-31$7.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-01-01 to 2025-03-31−$24.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31−$1.89us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31−$1.89us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-01-01 to 2025-03-3113,114,804 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2025-01-01 to 2025-03-31−$14.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-01-01 to 2025-03-31$4.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2025-01-01 to 2025-03-31$300.0kus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2025-03-31$33.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$371.5mus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$868.0mus-gaap:Assets
Current liabilitiesAt period end2025-03-31$847.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-03-31$1.04bnus-gaap:Liabilities
Current portion of debtAt period end2025-03-31$523.5mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2025-03-31−$204.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001006837-25-000045. Last ingested by Listed: Nov 14, 2026, 23:42 ET. Listed shows no prices and gives no investment advice.